


# 1 Ethyl Loflazepate

2 ロフラゼパ酸エチル



and enantiomer

3  
4  $C_{18}H_{14}ClFN_2O_3$ : 360.77

5 Ethyl (3*RS*)-7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1*H*-1,4-  
6 benzodiazepine-3-carboxylate

7 [29177-84-2]

8

9 Ethyl Loflazepate, when dried, contains not less  
10 than 98.5% and not more than 102.0% of ethyl  
11 loflazepate ( $C_{18}H_{14}ClFN_2O_3$ ).

12 **Description** Ethyl Loflazepate occurs as a white crystal-  
13 line powder.

14 It is sparingly soluble in acetonitrile, slightly soluble in  
15 ethanol (99.5), and practically insoluble in water.

16 It shows no optical rotation.

17 Melting point: About 199°C (with decomposition).

18 **Identification** (1) Determine the absorption spectrum  
19 of a solution of Ethyl Loflazepate in acetonitrile (1 in  
20 100,000) as directed under Ultraviolet-visible Spectropho-  
21 tometry <2.24>, and compare the spectrum with the Refer-  
22 ence Spectrum or the spectrum of a solution of Ethyl  
23 Loflazepate RS prepared in the same manner as the sample  
24 solution: both spectra exhibit similar intensities of absorp-  
25 tion at the same wavelengths.

26 (2) Determine the infrared absorption spectrum of  
27 Ethyl Loflazepate, previously dried, as directed in the po-  
28 tassium bromide disk method under Infrared Spectropho-  
29 tometry <2.25>, and compare the spectrum with the Refer-  
30 ence Spectrum or the spectrum of dried Ethyl Loflazepate  
31 RS: both spectra exhibit similar intensities of absorption at  
32 the same wave numbers.

33 **Purity** (1) Soluble halides — To 1.0 g of Ethyl  
34 Loflazepate add 50 mL of water, allow to stand for 1 hour  
35 with occasional shaking, and filter. Discard the first 10 mL  
36 of the filtrate, transfer 25 mL of the subsequent filtrate to a  
37 Nessler tube, add 6 mL of dilute nitric acid and water to  
38 make 50 mL, and use this solution as the test solution. Pro-  
39 ceed as directed under Chloride Limit Test <1.03>. Prepare  
40 the control solution as follows: to 0.20 mL of 0.01 mol/L  
41 hydrochloric acid VS add 6 mL of dilute nitric acid and wa-  
42 ter to make 50 mL.

43 (2) Heavy metals — Proceed with 1.0 g of Ethyl  
44 Loflazepate according to Method 2, and perform the test.

45 Prepare the control solution with 2.0 mL of Standard Lead  
46 Solution (not more than 20 ppm).

47 (3) Arsenic <1.11>— Prepare the test solution with 1.0  
48 g of Ethyl Loflazepate according to Method 3, and perform  
49 the test (not more than 2 ppm).

50 (4) Related substances — Dissolve 20 mg of Ethyl  
51 Loflazepate in 20 mL of the mobile phase, and use this so-  
52 lution as the sample solution. Pipet 1 mL of the sample so-  
53 lution, add the mobile phase to make exactly 100 mL, and  
54 use this solution as the standard solution. Perform the test  
55 with exactly 5  $\mu$ L each of the sample solution and standard  
56 solution as directed under Liquid Chromatography <2.01>  
57 according to the following conditions, and determine each  
58 peak area by the automatic integration method: the peak  
59 area of the related substance A, having the relative retention  
60 time of about 1.15 to ethyl loflazepate, from the sample so-  
61 lution is not larger than 1/5 times the peak area of ethyl  
62 loflazepate from the standard solution, the peak area of the  
63 related substance B, having the relative retention time of  
64 about 1.38, from the sample solution is not larger than 7/10  
65 times the peak area of ethyl loflazepate from the standard  
66 solution, and the area of the peak other than ethyl  
67 loflazepate and the peaks mentioned above from the sample  
68 solution is not larger than 1/10 times the peak area of ethyl  
69 loflazepate from the standard solution. Furthermore, the to-  
70 tal area of the peaks other than ethyl loflazepate from the  
71 sample solution is not larger than the peak area of ethyl  
72 loflazepate from the standard solution.

73 *Operating conditions*—

74 Detector: An ultraviolet absorption photometer  
75 (wavelength: 254 nm).

76 Column: A stainless steel column 4.6 mm in inside  
77 diameter and 15 cm in length, packed with  
78 octadecylsilanized silica gel for liquid chromatography (5  
79  $\mu$ m in particle diameter).

80 Column temperature: A constant temperature of about  
81 25°C.

82 Mobile phase: Dissolve 3.9 g of sodium dihydrogen  
83 phosphate dihydrate in water to make 1000 mL, and adjust  
84 to pH 6.0 with a solution prepared by dissolving 9.0 g of  
85 disodium hydrogen phosphate dodecahydrate in water to  
86 make 1000 mL. To 500 mL of this solution add 500 mL of  
87 acetonitrile for liquid chromatography.

88 Flow rate: Adjust so that the retention time of ethyl  
89 loflazepate is about 10 minutes.

90 Time span of measurement: About 3 times as long as the  
91 retention time of ethyl loflazepate.

92 *System suitability*—

93 Test for required detectability: Pipet 1 mL of the standard  
94 solution, and add the mobile phase to make exactly 20 mL.  
95 Confirm that the peak area of ethyl loflazepate obtained

96 with 5  $\mu\text{L}$  of this solution is equivalent to 4 to 6% of that  
97 with 5  $\mu\text{L}$  of the standard solution.

98 System performance: When the procedure is run with 5  
99  $\mu\text{L}$  of the standard solution under the above operating  
100 conditions, the number of theoretical plates and the  
101 symmetry factor of the peak of ethyl loflazepate are not less  
102 than 2500 and not more than 2.0, respectively.

103 System repeatability: When the test is repeated 6 times  
104 with 5  $\mu\text{L}$  of the standard solution under the above operating  
105 conditions, the relative standard deviation of the peak area  
106 of ethyl loflazepate is not more than 2.0%.

107 **Loss on drying** <2.41> Not more than 0.2% (0.2 g, 105°C,  
108 3 hours).

109 **Residue on ignition** <2.44> Not more than 0.1% (0.5 g).

110 **Assay** Weigh accurately about 10 mg each of Ethyl  
111 Loflazepate and Ethyl Loflazepate RS, both previously  
112 dried, add the internal standard solution to dissolve to make  
113 exactly 100 mL, and use these solutions as the sample solu-  
114 tion and the standard solution, respectively. Perform the test  
115 with 10  $\mu\text{L}$  each of the sample solution and standard solu-  
116 tion as directed under Liquid Chromatography <2.01> ac-  
117 cording to the following conditions, and calculate the ratios,  
118  $Q_T$  and  $Q_S$ , of the peak area of ethyl loflazepate to that of  
119 the internal standard.

120 Amount (mg) of ethyl loflazepate ( $\text{C}_{18}\text{H}_{14}\text{ClFN}_2\text{O}_3$ )  
121  $= M_S \times Q_T / Q_S$

122  $M_S$ : Amount (mg) of Ethyl Loflazepate RS taken

123 *Internal standard solution*—A solution of methyl parahy-  
124 droxybenzoate in acetonitrile for liquid chromatography (1  
125 in 3000).

126 *Operating conditions*—

127 Detector: An ultraviolet absorption photometer  
128 (wavelength: 229 nm).

129 Column: A stainless steel column 4.0 mm in inside  
130 diameter and 25 cm in length, packed with  
131 octadecylsilanized silica gel for liquid chromatography (7  
132  $\mu\text{m}$  in particle diameter).

133 Column temperature: A constant temperature of about  
134 25°C.

135 Mobile phase: A mixture of water, acetonitrile for liquid  
136 chromatography and ethanol (95) (2:1:1).

137 Flow rate: Adjust so that the retention time of ethyl  
138 loflazepate is about 13 minutes.

139 *System suitability*—

140 System performance: When the procedure is run with 10  
141  $\mu\text{L}$  of the standard solution under the above operating  
142 conditions, the internal standard and ethyl loflazepate are  
143 eluted in this order with the resolution between these peaks  
144 being not less than 6.


145 System repeatability: When the test is repeated 6 times  
146 with 10  $\mu\text{L}$  of the standard solution under the above  
147 operating conditions, the relative standard deviation of the  
148 ratio of the peak area of ethyl loflazepate to that of the  
149 internal standard is not more than 1.0%.

150 **Containers and storage** Containers—Tight containers.

151 **Others**

152 Related substance A:


153 Ethyl 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzo-  
154 diazepine-3-carboxylate



155

156 Related substance B:

157 Propyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-  
158 1,4-benzodiazepine-3-carboxylate



159

160 **Add the following to 9.01 Reference**  
161 **Standards (1):**

162 **Ethyl Loflazepate RS**